FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Börse Stuttgart 19:50:09 07/06/2024 BST | ||
| 0.31 EUR | +3.33% |
|
| 3 months | +3.33% | ||
| 6 months | +19.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.31 | +3.33% |
| 06/06/24 | 0.3 | +3.45% |
| 05/06/24 | 0.29 | -3.33% |
| 04/06/24 | 0.3 | 0.00% |
| 03/06/24 | 0.3 | -3.23% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 07:50 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MF1J62 |
| ISIN | DE000MF1J629 |
| Date issued | 06/02/2017 |
| Strike | 2,911 kr |
| Maturity | Unlimited |
| Parity | 423.11 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.57 € |
|---|---|
| Lowest since issue | 0.145 € |
| Spread | 0.01 € |
| Spread % | 3.13% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.67%
- Stock Market
- Certificates
- Certificat
